SAHA-based novel HDAC inhibitor design by core hopping method.

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Computational Drug Design

Background:

• Histone deacetylase (HDAC) inhibitors are crucial in cancer therapy, with SAHA showing efficacy against T-cell lymphoma.
• SAHA exhibits limitations including poor pharmacokinetics and severe toxicities, necessitating the development of improved inhibitors.

Purpose of the Study:

• To design novel, high-efficiency HDAC inhibitors with enhanced ADMET properties.
• To identify SAHA analogs with improved binding affinity and interactions with the HDAC-8 active site.

Main Methods:

• Core hopping of SAHA to create a compound database.
• Molecular docking of compounds into the HDAC-8 active site (PDB ID: 1T69).
• ADMET prediction and molecular dynamics simulation of lead compounds.

Main Results:

• Several candidate compounds with higher docking scores and improved interactions with the catalytic zinc ion were identified.
• Ten compounds with favorable ADMET predictions were selected.
• Molecular dynamics simulations confirmed the stability of the HDAC8-inhibitor system for a representative compound.

Conclusions:

• The study presents a viable strategy for designing novel HDAC inhibitors with superior efficacy and ADMET profiles.
• This approach holds promise for developing improved anti-cancer agents targeting HDACs.